Офтальмол. журн. — 2017. — № 5. — С. 60-65.

УДК  617.723-002-085:615.27 (048.8)

https://doi.org/10.31288/oftalmolzh201756065

Применение биологической терапии в лечении увеитов. Современные тенденции

А. В. Зборовская, д-р мед. наук, А. В. Дорохова, канд. мед. наук

ГУ «Институт глазных болезней и тканевой терапии им. В.П. Филатова НАМН Украины»

Одесса (Украина)

E-mail:  filatov.uveitis@gmail.com          

Увеит является причиной слепоты приблизительно в 10% случаев. Согласно множеству проведенных исследований, фактор некроза опухолей-α (ФНО-α) играет важную роль в развитии увеита. Ингибиторы ФНО-α активно применяются в ревматологии, а в последнее время и в офтальмологии. Проведен анализ литературы относительно использования ингибиторов ФНО-α при увеитах. Достаточно крупные исследования и показали хорошие результаты применения ингибиторов ФНО-α при увеитах на фоне ювенильного идиопатического артрита, болезни Бехчета, анкилозирующих спондилоартропатий, саркоидоза. Профиль побочных еффектов и безопасность ингибиторов ФНО-α в целом приемлемы для применения в клинической практике. Ингибиторы ФНО-α обладают кортикостероид-сберегающим эффектом, что позволяет снизить связанные с лечением побочные реакции при высокой эффективности терапии.

Ключевые слова: увеит, ингибитор ФНО-α, адалимумаб

Литература

1.Balevic S. J. Profile of adalimumab and its potential in the treatment of uveitis / S. J. Balevic, C. E. Rabinovich // Drug Des Devel Ther. – 2016. – Vol. 10. – P. 2997–3003.

2.Becker M. D. The role of T cells in autoimmune uveitis / M. D. Becker, G. Adamus, M. P. Davey, J. T. Rosenbaum // Ocul Immunol Inflamm. – 2000. –Vol. 8. – P. 93–100.

3.Bloch-Michel E. International Uveitis Study Group: recommendations for the evaluation of intraocular inflammatory disease / E. Bloch-Michel, R..B. Nussenblatt // Am. J. Ophthalmol. – 1987. – Vol. 103. – P. 234–235. 

4.Callejas-Rubio J. L. Adalimumab therapy for refractory uveitis: a pilot study [letter] / J. L. Callejas-Rubio, D. Sánchez-Cano, J. L. García Serrano [et al] // J. Ocul. Pharmacol. Ther. – 2008. – Vol. 24. – P. 613–614.

5.Castiblanco С. Review of Systemic Immunosuppression for Autoimmune Uveitis / С. Castiblanco, Foster C. Stephen // Ophthalmol. Ther. – 2014. – Vol. 3(1-2). – P. 17–36.

6.Chang J. H. Uveitis: a global perspective / J. H. Chang, D. Wakefield // Ocul. Immunol. Inflamm. – 2002. – Vol. 10. – P.263–279.

7.Diak P. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration / P. Diak, J. Siegel, L. La Grenade, L. Choi [et al] // Arthritis Rheum. – 2010. – Vol. 62 (8). – P.2517–2524.

8.Diaz-Llopis M. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients / M. Diaz-Llopis, D. Salom, C. Garcia-de-Vicuna // Ophthalmology. – 2012. – Vol. 119(8). – P. 1575–1581.

9.Dick A. D. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment / A. D. Dick // Int. Ophthalmol. Clin. – 2000. – Vol. 40(2) P. 1–18.

10.Dunn J. P. Uveitis. / J. P. Dunn // Prim Care. – 2015. – Vol. 42(3). – P. 305–323.

11.Durrani K. Adalimumab for ocular inflammation / K. Durrani, J. H. Kempen, G.S. // Ying Ocul Immunol Inflamm. – 2016. – P. 1–8.

12.Erckens R. J. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis / R. J. Erckens, R. L. Mostard, P. A. Wijnen, [et al] // Graefes Arch Clin Exp Ophthalmol. –2012. – Vol. 250(5). –P. 713–720.

13.Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis / M. Feldmann // Nat Rev Immunol. – 2002. – Vol. 2(5). – P. 364–371.

14.Jabs D. A. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop / D. A. Jabs, R. B. Nussenblatt, J. T. Rosenbaum // Am J Ophthalmol. – 2005. – Vol. 140(3). – P. 509-516.

15.Hamam R. N. Intravitreal adalimumab in active noninfectious uveitis: a pilot study / R.N. Hamam, A. W. Barikian, R. S. Antonios [et al] // Ocul Immunol Inflamm. – 2016. – Vol. 24(3). – P. 319–326.

16.Imrie F. R. Biologics in the treatment of uveitis / F. R. Imrie, A. D. Dick // Curr Opin Ophthalmol. – 2007. – Vol. 18. – P. 481– 486.

17.Levy-Clarke G. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders / G. Levy-Clarke, D. A. Jabs, R.W. Read [et. al] // Ophthalmology. 2014. – Vol. 121(3). – P. 785–796.

18.Lightman S. Immunopathology and altered immunity in posterior uveitis in man: a review / S. Lightman, H. Towler // Curr Eye Res. – 1992. – Vol. 11. – P. 11–15.

19.Mahendradas P. Quantification of inflammation in inflammatory eye diseases / P. Mahendradas, A. Khanna, A. Kawali, [et al] // Internet journal of rheumatology and and clinical immunology. – 2014. – Vol. 2. – Р. 1. 

20.Makamura S. The role of tumor–necrosis factor alpha in the induction of experimental autoimmune uveoretinitis in mice / S. Makamura, T. Yamakawa, M. Sugita [et al] // Invest Ophthalm Vis Sei,. – 1994. – Vol. 35. – P. 3884–89.

21.Mariette X. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis / X. Mariette, M. Matucci-Cerinic, K.Pavelka [et al] // Ann Rheum Dis. – 2011. – Vol. – 70 (11). – P. 1895–1904.

22.Mo J.S. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis / J.S. Mo, A. Matsukawa, S. Ohkawara [et al.] // Exp Eye Res. – 1998. – Vol. –66(5). – P. 547–557.

23.Murray P. I. Anti-TNF-alpha therapy for uveitis: Behçet and beyond / P. I. Murray, R. R. // Sivaraj Eye (Lond). – 2005. – Vol. 19. – P. 831– 838.

24.Neri P. Adalimumab (Humira): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology / P. Neri, M. Zucchi, P. Allegri // Int Ophthalmol. – 2011. – Vol. 31(2). P. 165–173.

25.Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists / I. Nestorov // J Rheumatol Suppl. – 2005. – Vol. 74. – P. 13–18.

26.Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? / I. Nestorov // Semin Arthritis Rheum. 2005. – Vol. 34(5 Suppl 1). P. – 12–18.

27.Park H. J. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted? / H. J. Park, P. Ranganathan // Discov Med. 2012. – Vol. 13(70). – P. 229–234.

28.Pérez-Guijo V. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27 / V. Pérez-Guijo, M. Santos-Lacomba, M. Sánchez-Hernández // Curr Med Res Opin – 2004. – Vol. 20. – P. 155–157.

29.Rabinovich C.E. Use of tumor necrosis factor inhibitors in uveitis / C.E. Rabinovich // Curr Opin Rheumatol. – 2007. – Vol. 19(5). – P. 482–486.

30.Rajesh K. Spondyloarthropathies / K. Rajesh, D. O. Kataria, H. Lawrence [et al] //Am Fam Physician. – 2004. – Vol. 69(12). – P. 2853-2860.

31.Ramanan A. V. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial) / A. V. Ramanan, A. D. Dick, D. Benton [et al] // Trials. – 2014. – Vol. 15. – P. 14.

32.Ramanan A. V. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis [abstract] / A. V. Ramanan, A. D. Dick, A. McKay // Arthritis Rheumatol. – 2015. – Vol. – 67 (Suppl 10).

33.Rothova A. Uveitis and systemic diseas / A. Rothova, H.J. Buitenhuis, C. Meenken [et al.] // Br J Ophthalmol. – 1992. – Vol.76. – P. 137– 141.

34.Rudwaleit M. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study / M. Rudwaleit, E. Rodevand, P. Holck [et al] // Ann Rheum Dis. 2009. – Vol. 68(5). – P. 696–701.

35.Santos Lacomba M. Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis / M. Santos Lacomba, C. Marcos Martín, J.M. Gallardo Galera [et al] // Ophthalmic Res. – 2001. – Vol. 33. – P. 251–255.

36.Sarah L. Juvenile idiopathic arthritis-associated uveitis / L. Sarah, N. Clarke, S. Ethan // Pediatric Rheumatology. – 2016. – Vol. 14. – P. 27 

37.Sartani G. Anti–tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming / G. Sartani // Invest Ophthalmol Vis Sci. – 1996. – Vol. 37. –P. 2211–2218.

38.Schmeling H. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry / H. Schmeling, K. Minden, I. Foeldvari [et al] // Arthritis Rheumatol. 2014. – Vol. 66(9). – P. 2580–2589.

39.Simonini G. Prevention of flare recurrences in childhood refractory chronic uveitis: an openlabel comparative study of adalimumab versus infliximab / G.Simonini, A. Taddio, M. Cattalini [et al.] //Arthitis Care Res (Hoboken).–2011–Vol. 63. P. 612– 618.

40.Simonini G. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs / G. Simonini, K. Druce, R. Cimaz, [et al] // Arthritis Care Res (Hoboken). – 2014. – Vol. 66(7). – P. 1073–1084.

41.Smit R. L. Epidemiology of uveitis / R. Smit, G. Baarsma // Curr Opin Ophthalmol. – 1995. – Vol. 6. – P.57– 61.

42.Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. – 2005. – Vol. 140(3). – P.509–516.

43.Suhler E. B. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. / Suhler E. B., Lowder C. Y., Goldstein D. A. // Br J Ophthalmol. – 2013. – Vol. 97(4). – P. 481–486.

44.Takase K. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis / K. Takase, S. Ohno, H. Ideguchi [et al] // Rheumatol Int. – 2011. – Vol. 31. – P. 243–245.

45.Taylor S. R. New developments in corticosteroid therapy for uveitis / S. R. Taylor, H. Isa, L. Joshi [et al] // Ophthalmologica. – 2010. – Vol. 224. –P. 46 –53.

46.Tracey D. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review / D. Tracey, L. Klareskog, E. H. Sasso [et al] // Pharmacol Ther. – 2008. – Vol. 117(2). – P. 244–279.

47.Vallet H. Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients / H. Vallet, S. Riviere, A. Sanna [et al.] // J Autoimmun. – 2015. – Vol. 62. – P. 67–74.

48.Zannin M.E. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian Registry / M.E. Zannin, C. Birolo, V.M. Gerloni [et al] // J Rheumatol. 2013. – Vol. 40(1). – P. 74–79.

49.Zeboulon N. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review / N. Zeboulon, M. Dougados, L. Gossec // Ann Rheum Dis. – 2008. – Vol. 67(7). – P. 955–959.

50.Инструкция для медицинского применения лекарственного средства Хумира®. Приказ МЗ Украины № 247 от 09.03.2017 (в виде предварительно наполненного шприца, содержащего 40 мг адалимумаба в 0,8 мл раствора). Регистрационное удостоверение № UA/13612/01/01.

51.Jaffe G., Dick A., Brezin A.  et al. Adalimumab in Patients with Active Noninfectious Uveitis / Jaffe G., Dick A., Brezin A., [et al] // N Engl J Med. – 2016. – Vol. 375. –P.932-943

 

52.Nguyen Q.,  Merrill P., Jaffe G., Dick A. et al.  Adalimumab for prevention of uveitic fl are in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. / Nguyen Q.,  Merrill P., Jaffe G., Dick A., [et al] //  Lancet. – 2016. – Vol. 388. – P.1183–1192.